⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 30, 2024Expert Opinion on Drug Safety

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA adverse event reporting system

Dehua Zhao Xiaoqing Long Jisheng Wang

View at Publisher

Ask AI

Bookmark

Share

Abstract

Background To data, there is insufficient large-scale data on the adverse events (AEs) of pemigatinib. Consequently, we conducted a pharmacovigilance study utilizing the Food and Drug Administration Adverse Event Reporting System (FAERS) database to investigate these AEs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhao et al. (2024) studied this question.

synapsesocial.com/papers/68e719e8b6db6435876938d5 https://doi.org/10.1080/14740338.2024.2338250

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparative safety of futibatinib vs pemigatinib in metastatic cholangiocarcinoma: FAERS-based analysis.Original Research · 2026
2Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US2024 · 11 citations
3A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib2024 · 1 citations
4Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations2024 · 4 citations
5Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) databaseOriginal Research · 2025 · 2 citations

More related papers

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies2024
Real-world patient characteristics and utilization patterns in patients with cholangiocarcinoma who received pemigatinib in the United States of America2026
Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database2026

More from Expert Opinion on Drug Safety

Long-term safety of treatment of hemophilia A: a comprehensive reviewTue,
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCTWed,